) on days 1-14, q4w (FEC arm). We compared both arms with respect to toxicity and feasibility. Results: Hematological toxicity was found significantly more often in the FEC arm. Febrile neutropenia was seen in 11.3% of patients in the FEC arm and in 8.4% of patients in the EC-Doc arm (p = 0.027). Non-hematological side effects of grade 3/4 were rarely seen in either arm. Therapy was terminated due to toxicity in 3.7% of the patients in the EC-Doc arm and in 8.0% of the patients in the FEC arm (p = 0.0009).
) on days 1-14, q4w (FEC arm). We compared both arms with respect to toxicity and feasibility. Results: Hematological toxicity was found significantly more often in the FEC arm. Febrile neutropenia was seen in 11.3% of patients in the FEC arm and in 8.4% of patients in the EC-Doc arm (p = 0.027). Non-hematological side effects of grade 3/4 were rarely seen in either arm. Therapy was terminated due to toxicity in 3.7% of the patients in the EC-Doc arm and in 8.0% of the patients in the FEC arm (p = 0.0009).
Conclusion:
The sequential anthracycline-taxane regimen is a well-tolerated and feasible alternative to FEC120 therapy.
Introduction
Adjuvant chemotherapy reduces the risk of cancer recurrence for patients with high-risk breast cancer [1] . However, the side effects of chemotherapy may cause problems that can even be life threatening. Therefore, it is of great importance to identify effective and well-tolerated chemotherapy regimens. In an effort to prolong disease-free and overall survival, doxorucibin-or epirubicin-based regimens have replaced CMF (cyclophosphamide, methotrexate, fluorouracil) as the standard chemotherapy used in the adjuvant situations [2] [3] [4] [5] .
The 2 widely-used FEC (fluorouracil, epirubicin, cyclophosphamide) regimens are the dose-dense FEC120 ( [2, 6] . Commonly observed side effects of FEC chemotherapy are myelosuppression, febrile neutropenia, mucositis, nausea, vomiting and alopecia; each of those can cause great damage to the patients. FEC120 chemotherapy that delivers a cumulative dose of 720 mg epirubicin is thought to be more toxic than FEC100. Although studies comparing FEC100 and FEC120 are not available, cardiotoxicity can be assumed to be a major problem of the higher anthracycline dose.
Taxanes have been added to chemotherapy regimens to improve the efficiency of breast cancer treatment. Initially, in the metastatic setting, they were superior to anthracyclines [7] [8] [9] . In the adjuvant situation, meta-analytic data showed a significant increase in disease-free and overall survival rates for patients following taxane therapy, in particular for patients with node-positive breast cancers [10] [11] [12] [13] [14] [15] . On the other hand, treatment with the taxane compound docetaxel had shown severe side effects for patients, including neutropenia (76.4%), anemia (8.9%), neurological symptoms (4%), stomatitis (5.3%), and dermal affections (5.9%).
In the present study, we investigated the feasibility of epirubicin-based chemotherapy with or without a taxane by evaluating chemotherapy-induced toxicity in data from the ADEBAR trial.
Patients and Methods
The ADEBAR trial was a multicenter phase III trial for patients with high-risk breast cancer (≥ 4 involved lymph nodes). The trial primarily served to compare recurrence-free survival rates, and further aims were to compare overall survival, quality of life, and toxicity.
Chemotherapy
Patients were prospectively randomized into 2 groups. For patients in Arm A (EC-Doc), 4 cycles of epirubicin at 90 mg/m 2 and cyclophosphamide at 600 mg/m 2 (EC) every 3 weeks (q3w) were followed by 4 cycles of docetaxel at 100 mg/m 2 (Doc) q3w. For patients in Arm B (FEC 120 ), 6 cycles of epirubicin at 60 mg/m 2 and 5-fluorouracil at 500 mg/m 2 i.v. were given on days 1+8 with cyclophosphamide at 75 mg/m 2 p.o. on days 1-14, q4w.
Co-Medication and Supportive Care
Patients received co-medication with dexamethasone, mesna (sodium 2-sulfanylethanesulfonate) and 5-HT3 antagonists. According to the study design, granulocyte colony-stimulating factor (G-CSF), erythropoietin and antibiotics were given when required. G-CSF was applied as a secondary prophylaxis in the following cases: febrile neutropenia; neutropenia (absolute neutrophil count (ANC) < 0.5 × 10 9 /l) lasting more than 5 days; severe neutropenia (ANC < 0.1 × 10 9 /l); and if an extension of the therapy interval was necessary due to insufficient levels of leukocytes (< 3.0 × 10 9 /l) or neutrophils (ANC < 1.5 × 10 9 /l). Erythropoietin (300 mg/q2w or 150 mg/q1w) was recommended for chemotherapy-associated anemia (≤ 11 g/dl), or if hemoglobin levels decreased more than 3 g/dl in 3 months. Prophylactic oral antibiotics were recommended if the levels of neutrophil granulocytes were < 0.5 × 10 9 /l, regardless of G-CSF application. For febrile neutropenia, hospitalization and i.v. antibiotic therapies were recommended in the study protocol.
Delay and Dose Reduction
Chemotherapy was delayed for a maximum of 2 weeks in cases of hematological or non-hematological toxicity. A dose reduction by 1 level was performed successively for cases of severe hematological toxicity where secondary prophylactic application of G-CSF was unsuccessful. Nonhematological toxicities of grade 3 or 4 led to either a dose reduction or termination of the therapy. Minor cardiac symptoms, including isolated asymptomatic ventricular extrasystoles, were monitored, and patients were allowed to continue treatment. However, patients were removed from the study when arrhythmias required treatment or there was a significant reduction in left ventricular ejection fraction (LVEF) (Study protocol of the ADEBAR-Trial, Version 3.0, 07/2003, 1).
Data Collection
Data were collected using online clinical response forms. Data quality was controlled by a clinical research organization (CRO), which visited and monitored the study centers. Therapy-associated toxicity was evaluated using the Common Toxicity Criteria of the NCI (National Cancer Institute), once before each chemotherapy cycle, and once 28 days after the end of chemotherapy. Electrocardiography (ECG) was performed before each chemotherapy cycle and once 28 days after the end of chemotherapy, and echocardiography just before chemotherapy and 6 month after the last cycle or when cardiac symptoms occurred.
Statistical Analysis
Therapy-associated toxicities were compared using the χ 2 test; Fisher's exact test was used for cases of cell frequencies that were less than 5. A value of p < 0.05 was considered significant in 2-sided tests. No adjustments of the error probability for multiplicity were performed. All analyses were performed using Statistical Analysis Software Version 9.2 (SAS Institute Inc., Cary, NC, USA). 
Results

From
Hematological Toxicity during the Course of EC-Doc Therapy
Significantly less leukopenia of grades 3 and 4 was found during the application of EC (55.8%) than during the subsequent application of docetaxel (76.9%) (p < 0.001). The rates of neutropenia were similar, as 62.5% of patients receiving EC and 57.9% of those receiving docetaxel therapy (p = 0.291) developed this condition. Although G-CSF was given more often during docetaxel than EC therapy (26.2% vs. 11.3%; p < 0.0001), the higher incidence of leukopenia during docetaxel therapy could not be avoided. Anemia rarely occurred during the application of docetaxel (1.5%), but was found in 7.5% of patients during the application of EC (p < 0.001). The most frequently observed event in the EC-Doc group as pain (14.2%), especially arthralgia and myalgia (12.3%), which was seldom found in the FEC group (pain 3.6% and arthralgia/myalgia 1.4%; p < 0.001). There was a significant difference in the frequency of patients who experienced severe vomiting between the EC-Doc (6.2%) and FEC (2.8%) groups (p = 0.003). Neurological symptoms of grade 3 or 4 and skin affections occurred almost exclusively in the EC-Doc group (vs. FEC group) with 3.9% (0.3%) and 4.2% of patients (0.8%) (p < 0.001), respectively, having these conditions. This effect was mostly due to the administration of docetaxel in the EC-Doc group. Cardiac impairments according to NCI criteria of grade 3 or 4 were rare, and their frequencies were not statistically different between groups (1.1% FEC vs. 0.3% EC-Doc) (p = 0.1). Severe edema was also seldom found, but occurred significantly more often in the EC-Doc group (2.6%) than in the FEC group (0.3%) (p < 0.001).
Dose Reduction, Treatment Delay, Treatment Termination and Death during the Trial
The full set of chemotherapy cycles outlined in the study protocol was administered to 80.3% of patients in the EC-Doc group and to 77.1% of patients in the FEC group (p = 0.16).
Erythropoietin was administered more often during docetaxel (4.3%) than during EC (1.9%) therapy (p < 0.0001), although the rate of anemia was higher during EC therapy.
Hematological Toxicity during the Course of FEC
During the 6 cycles of therapy for the FEC group, anemia grade 3/4 was observed in approximately 15% of the patients. There was greater use of erythropoietin in this treatment group; it was given to 6.3% of patients in the first 3 cycles and to 12.7% during the second 3 cycles (p < 0.0001). We found a similar phenomenon for thrombopenia; there were more grade 3 and 4 events in the second half of FEC therapy (25.3%) than in the first half of therapy (18%) (p = 0.079). During the application of FEC, the percentages of patients with leukopenia and neutropenia remained steady, although there were small decreases from the initial levels of 81.6% to 79.2% (p = 0.49) in cycles 1-3 and from 68.4% to 58.0% (p = 0.013) in cycles 4-6. This correlated with an increased administration of G-CSF in the second half of FEC (47.4% vs. 32.1% in the first half; p < 0.0001).
Non-Hematological Toxicity
In contrast to hematological toxicities, severe non-hematological toxicities of grades 3 and 4 (table 3) were rarely found. cycline-based regimen. No existing studies have directly compared FEC120 therapy with FEC100, but it is likely that the FEC120 group would have higher levels of toxicity because of the greater cumulative amount of chemotherapeutic agents. Hematological toxicity and its complications are the greatest challenge in adjuvant chemotherapy for breast cancer. Our data analysis has shown that hematological toxicity, especially neutropenia, is the main side effect of anthracycline and taxane-based chemotherapy, as also observed in the NSABP-B-28 and the PACS-01 trials [10, 12, 21] . We found myelotoxicity to be the most common toxicity of grade 3/4 for both groups. The high rate of neutropenia (approximately 60%) was managed well with secondary G-CSF treatment. Primary application of G-CSF or pegfilgastrim in other docetaxel regimens could have influenced the comparability of the toxicity data [22] . According to the PACS 01 trial, anemia and thrombocytopenia were not the main complications resulting from taxane-based therapy [12, 21] , while these complications occurred more often during FEC therapy. Overall, hematological toxicity was seen to be the most frequent side effect in FEC120 therapy. Febrile neutropenia occurred in 11.3% (FEC) and 8.4% (EC-Doc) of patients. Similar rates of febrile neutropenia were seen in the sequential anthracycline-taxane arm of the BCIRG 005 trial (8.3%) and in the PACS01 trial (11%) [12] . Overall, the rates of hematological toxicities in the ADEBAR trial are equivalent to those seen in other trials.
Severe non-hematological side effects were mainly associated with taxane therapy. Arthralgia and myalgia (12.3%) were major complications in the EC-Doc group, but were seldom found in the FEC group (< 4%). Severe docetaxelassociated neurotoxicity and skin affection were each found in 4% of patients in the taxane group and in < 1% of patients in the anthracycline group. Patients with neurological toxicities of an NCI grade > 2 were removed from the trial. The NSABP-B28 trial found a similar rate of arthralgia and/or myalgia in patients from the taxane arm (12%), but a higher rate of neurotoxicity in patients (15%) who received paclitaxel [10] . Long-term data regarding neurotoxicity from the ADEBAR trial are not yet available, and need to be the subject of further evaluation.
Anthracycline-associated cardiac impairments seldom occurred during the observation period. Cardiac symptoms according to NCI toxicity score were routinely documented during and directly following chemotherapy. Overall, only 0.3% of patients in the EC-Doc group and 1.1% in the FEC group experienced cardiac-associated grade 3 or 4 adverse events. Cardiac toxicity could not be evaluated in the longterm-follow up of ADEBAR patients because no further echocardiographic examinations were performed. Regarding the cardiotoxicity of anthracyclines, the PACS-01 trial found a similar rate of cardiac events at the 5-year follow-up (FECDoc, 0.4%; FEC, 1.3%) [12] . The 10-year follow-up in the BCIRG 01 trial found the rate of cardiac problems of grade Twice as many patients in the FEC group (8.0%) as in the EC-Doc group (3.7%) terminated their therapy (p = 0.002) because of toxicity. The rate of denial was identical in both groups at 4.4%. There was no significant difference in the frequency of treatment termination due to tumor progression between groups (EC-Doc at 0.6%, FEC at 0.5%). 6 deaths occurred during the observation period. In the FEC group, 1 death was a result of a lung embolism, 1 resulted from perforated sigmadiverticulitis during leukopenia, and 2 were due to cardiac arrest. In the EC-Doc group, 1 death was caused by tumor progression (cerebral metastasis), and 1 by cardiac arrest. On the assessment by the investigators, these deaths were not thought to have been a result of the therapy.
Dose reduction was rarely used during the application of EC treatment (0.5%), but was used in 5% of patients during the docetaxel treatment cycles, in 3.2% of patients during the first cycle of FEC, and in 9.3% during the second cycle of FEC therapy. Dose reduction was more often required during FEC (12.5%) than during EC-Doc (5.5%) therapy (p = 0.046). 12% of patients receiving EC-Doc therapy and 17.2% receiving FEC therapy had extended time intervals between cycles (p < 0.001).
Discussion
Sequential anthracycline-taxane regimens have been reported to show good feasibility [11, 12] , whereas combined regimens have shown higher rates of hematological toxicity [9, 16] . For example, in the BCIRG 005 trial, docetaxel in combination with doxorubicin and cyclophosphamide (TAC) was associated with more febrile neutropenia [16] . The PACS 01 trial showed that, although patients had improved disease-free survival and overall survival following sequential taxane therapy (using a slightly different chemotherapy regimen than in the ADEBAR trial with 3× FEC, followed by 3× Doc), approximately 11% of them had febrile neutropenia [12] .
As taxane-containing regimens are effective for nodal-positive as well as for nodal-negative patients [15, 17, 18] , this analysis of the toxicities resulting from sequential FEC-Doc therapy compared with taxane-free, but dose-dense, FEC120 therapy from the ADEBAR trial is a novel approach for evaluating the feasibility of these 2 treatment options. The treatment arm A (EC-Doc) was chosen in reference to the CALBG-9344 and NSABP-B27 trials [19, 20] . The dose of docetaxel used was selected for its approximate equivalence to the dose of paclitaxel used in the CALBG-9344 trial [19] . The treatment arm B (FEC) was chosen in reference to the Levine protocol. The Levine regimen has been shown to be superior in comparison with CMF therapy in a large randomized study [2] . The treatment duration for this regimen was identical to that of arm A. The toxicity resulting from application of the Levine protocol was high, but was indicative of what would have been expected in a dose-intensified anthra-
